Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD - Full Text View

Sponsors and Collaborators:	Eli Lilly and Company Alkermes
Information provided by:	Eli Lilly and Company
ClinicalTrials.gov Identifier:	NCT00157339

Purpose

Phase 3 , open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or COPD. Patients will be treated for 12 months with a 2 month follow up period.

Condition	Intervention	Phase
Diabetes Mellitus Asthma Pulmonary Disease, Chronic Obstructive	Drug: Human Insulin Inhalation Powder Drug: injected insulin	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma

Resource links provided by NLM:

MedlinePlus related topics: Asthma COPD (Chronic Obstructive Pulmonary Disease) Diabetes

Drug Information available for: Insulin

U.S. FDA Resources

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:

To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on FEV1 and FVC before and after inhalation of bronchodilator. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on the response to bronchodilator as measured by change between pre- and post- bronchodilator FEV1 and FVC [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on DLco. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on total lung capacity [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on safety as assessed by insulin antibody levels, adverse events, and episodes of hypoglycemia [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on safety as assessed by chest x-rays. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on safety as assessed by the St. George's Respiratory Questionnaire. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on safety as assessed by the Six-Minute Walk Test with the Borg CR10 Scale. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on proportion of patients who achieve or maintain HbA1c of less than or equal to 6.5% and who achieve or maintain HbA1c of < 7 %. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and inj. insulin on proportion of pts with type 2 on oral agent(s) rand. to Human Insulin Inhalation Powder only or glargine only who do not reach an HbA1c <7.5 % after six months. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on glycemic control as assessed by the 8-point-self monitored blood glucose profiles [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on insulin dose requirements ( including total, basal, and/or bolus insulin) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on patient-reported outcomes questionnaires to assess general health status. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on resource utilization. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To assess insulin inhaler reliability in patients randomized to treatment with Human Insulin Inhalation Powder. [ Time Frame: throughout the study ] [ Designated as safety issue: No ]
To explore the impact of Human Insulin Inhalation Powder on peak flow and peak flow variability in the study with asthma patients. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment:	299
Study Start Date:	August 2005
Study Completion Date:	May 2008
Primary Completion Date:	May 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Human Insulin Inhalation Powder patient specific dose, inhaled, before meals, 12 months
2: Active Comparator	Drug: injected insulin patient specific dose, injected, before meals, 12 months.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Type 1 or type 2 diabetes
asthma or COPD

Exclusion Criteria:

Current smoking habit

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00157339

Show 101 Study Locations

Sponsors and Collaborators

Eli Lilly and Company

Alkermes

Investigators

Study Director:

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hour, EST)

Eli Lilly and Company

More Information

Additional Information:

Lilly Clinical Trial Registry This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Eli Lilly ( Chief Medical Officer )
Study ID Numbers:	7091, H7U-MC-IDAS
Study First Received:	September 7, 2005
Last Updated:	July 3, 2008
ClinicalTrials.gov Identifier:	NCT00157339 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Metabolic Diseases
Bronchial Diseases
Diabetes Mellitus
Endocrine System Diseases
Asthma
Insulin
Lung Diseases, Obstructive
Hypersensitivity
Hypoglycemic Agents

Respiratory Tract Diseases
Lung Diseases
Hypersensitivity, Immediate
Chronic Disease
Endocrinopathy
Glucose Metabolism Disorders
Metabolic Disorder
Pulmonary Disease, Chronic Obstructive
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Disease Attributes
Metabolic Diseases
Bronchial Diseases
Immune System Diseases
Physiological Effects of Drugs
Diabetes Mellitus
Endocrine System Diseases
Asthma
Pharmacologic Actions
Insulin
Lung Diseases, Obstructive

Hypersensitivity
Hypoglycemic Agents
Pathologic Processes
Respiratory Tract Diseases
Lung Diseases
Hypersensitivity, Immediate
Chronic Disease
Glucose Metabolism Disorders
Pulmonary Disease, Chronic Obstructive
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on September 11, 2009